TEMP News & Analysis
2 articles
Market Mood
Tempus AI Stock Price Target Raised to $66 by H.C. Wainwright
H.C. Wainwright has raised the stock price target for Tempus AI to $66. This adjustment reflects the firm's updated outlook on the company's performance in the market. The new price target could potentially influence investor sentiment and trading behavior in the stock. Understanding this change is important for market participants who are evaluating Tempus AI's growth prospects.
Read More: Tempus AI Stock Price Target Raised to $66 by H.C. Wainwright
Tempus AI to Acquire Personalis for $1.5bn in Oncology Deal
Tempus AI will acquire Personalis for $1.5 billion in a stock deal set to close by early 2027, paying $16.25 per share—representing a 6% premium on Personalis' recent close of $15.39. Following the announcement on July 20, Tempus shares fell by 7.74%, closing at $48.41, while Personalis stock dropped 13.2% to $13.34. Despite a reported preliminary Q2 revenue of $22.4 million from Personalis and a 33% increase in MRD test volumes, concerns about profitability persist. This acquisition positions Tempus to enhance its oncology services, particularly in minimal residual disease testing, which is increasingly important for cancer patient monitoring.
Read More: Tempus AI to Acquire Personalis for $1.5bn in Oncology Deal